Tolerance development in cow's milk–allergic infants receiving amino acid–based formula: A randomized controlled trial

Pantipa Chatchatee, Anna Nowak-Wegrzyn, Lars Lange, Suwat Benjaponpitak, Kok Wee Chong, Pasuree Sangsupawanich, Marleen T.J. van Ampting*, Manon M. Oude Nijhuis, Lucien F. Harthoorn, Jane E. Langford, Jan Knol, Karen Knipping, Johan Garssen, Valerie Trendelenburg, Robert Pesek, Carla M. Davis, Antonella Muraro, Mich Erlewyn-Lajeunesse, Adam T. Fox, Louise J. MichaelisKirsten Beyer, Lee Noimark, Gary Stiefel, Uwe Schauer, Hamelman, Diego Peroni, Boner

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

4 Citations (Scopus)

Abstract

Background: Tolerance development is an important clinical outcome for infants with cow's milk allergy. Objective: This multicenter, prospective, randomized, double-blind, controlled clinical study (NTR3725) evaluated tolerance development to cow's milk (CM) and safety of an amino acid–based formula (AAF) including synbiotics (AAF-S) comprising prebiotic oligosaccharides (oligofructose, inulin) and probiotic Bifidobacterium breve M-16V in infants with confirmed IgE-mediated CM allergy. Methods: Subjects aged ≤13 months with IgE-mediated CM allergy were randomized to receive AAF-S (n = 80) or AAF (n = 89) for 12 months. Stratification was based on CM skin prick test wheal size and study site. After 12 and 24 months, CM tolerance was evaluated by double-blind, placebo-controlled food challenge. A logistic regression model used the all-subjects randomized data set. Results: At baseline, mean ± SD age was 9.36 ± 2.53 months. At 12 and 24 months, respectively, 49% and 62% of subjects were CM tolerant (AAF-S 45% and 64%; AAF 52% and 59%), and not differ significantly between groups. During the 12-month intervention, the number of subjects reporting at least 1 adverse event did not significantly differ between groups; however, fewer subjects required hospitalization due to serious adverse events categorized as infections in the AAF-S versus AAF group (9% vs 20%; P = .036). Conclusions: After 12 and 24 months, CM tolerance was not different between groups and was in line with natural outgrowth. Results suggest that during the intervention, fewer subjects receiving AAF-S required hospitalization due to infections.

Original languageEnglish
Pages (from-to)650-658.e5
JournalJournal of Allergy and Clinical Immunology
Volume149
Issue number2
Early online date2 Jul 2021
DOIs
Publication statusPublished - Feb 2022

Keywords

  • amino acid–based formula
  • Cow's milk allergy
  • infection
  • oral tolerance
  • prebiotics
  • probiotics
  • synbiotics

Fingerprint

Dive into the research topics of 'Tolerance development in cow's milk–allergic infants receiving amino acid–based formula: A randomized controlled trial'. Together they form a unique fingerprint.

Cite this